SUNLOC

SHL/SEC/2026 **November 13, 2026**

The Bombay Stock Exchange Limited
Listing Department,
1st Floor, New Trading Ring,
Rotunda Building,
Phiroze JeeJeeBhoy Towers, Dalal Street, Fort
Mumbai – 400 001.
Company Code: **537253**

The Calcutta Stock Exchange Ltd.
7, Lyons Range
Kolkata - 700 001 India

Dear Sir,

Sub. : **Outcome of the 271st Board Meeting held on 13.11.2026**

Pursuant to Regulation 30 of the SEBI (LODR) Regulations, 2015, we are pleased to inform, inter-alia the outcome of the Meeting of the Board of Directors of the Company held on Friday, November 13, 2026 as follows:

1. Approved the Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter/ 1st half year ended September 30, 2026 of the FY 2026-27. Copy of the approved Un-Audited Financial Results (standalone and consolidated) for the 2nd quarter/ 1st half year ended September 30, 2026 of the FY 2026-27 alongwith the Limited Review report thereon are enclosed herewith.
2. The 2nd term (of 5 years) of Mr. Rakesh Mohan, from the position of Non-Executive Independent Director of the Company expired on 10.11.2026 after his 2 (two) consecutive terms of appointment of 5 years each (total 10 years) as Non-Executive Independent Director in the Company.

The meeting was started at **4.10 p.m. and concluded at 6.05 p.m.**

You are requested to take the above information in your record and oblige us.

Thanking you,
Yours sincerely,
for **Sunil Healthcare Limited**

SATYENDU PATTNAIK
Digitally signed by SATYENDU PATTNAIK
Date: 2026.11.13 18:15:45 +05'30'

Satyendu Pattnaik
Company Secretary & Compliance Officer
FCS-7736
Encl. a/a

Sunil Healthcare Ltd.
38E/252-A, Vijay Tower, Opp Panchsheel Park Comm. Complex, New Delhi -110049
T: +91 -11-49435555/00, F: +91 -11-43850087 Email : info@sunilhealthcare.com, Web: www.sunilhealthcare.com
CIN No. : L24302DL1973PLC189662

Singhi & Co.
Chartered Accountants

Unit No. 1704, 17th Floor,
World Trade Tower, (WTT), DND Flyway,
Sector 16, Noida 201 301 (India)
T +91 (0120) 297 0005, 92055 75996
E newdelhi@singhico.com
www.singhico.com

Independent Auditor's Review Report on the Unaudited Standalone Financial Results of the Company for the quarter and half year ended September 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 as amended.

To the Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying statement of unaudited standalone financial results of Sunil Healthcare Limited ('the Company") for the quarter and half year ended September 30, 2026 ("Statement") . This Statement is the responsibility of the Company's Management and has been approved by the Board of Directors. Our responsibility is to issue a report on this Statement based on our review.

2. This Statement, which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagement (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For Singhi & Co.
Chartered Accountants
Firm Reg. No. 302049E

SINGHI & CO. NOIDA DELHI NCR Chartered Accountants

Bimal Kumar Sipani
Partner
Membership No. 088926
UDIN: 26088926LCJRZC6785

Place: Noida (Delhi-NCR)
Date: November 13, 2026

Singhi & Co.
Chartered Accountants

Unit No. 1704, 17th Floor,
World Trade Tower, (WTT), DND Flyway,
Sector 16, Noida 201 301 (India)
+91 (0120) 297 0005, 92055 75996
newdelhi@singhico.com

Independent Auditor's Review Report on Unaudited Consolidated Financial Results of the Company for the quarter and half year ended September 30, 2026 pursuant to the Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015, as amended

To Board of Directors of Sunil Healthcare Limited

1. We have reviewed the accompanying Statement of unaudited consolidated financial results of Sunil Healthcare Limited ('the Company/ the Parent') and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group") for the quarter and half year ended September 30, 2026 ("the Statement") being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended.


2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India. Our responsibility is to express a conclusion on the Statement based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

   We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following foreign subsidiaries:
   a) Sunil Healthcare Mexico Sa De CV
   b) Sunil Healthcare North America LLC

5. Based on our review conducted and procedures performed as stated in paragraph 3 above nothing has come to our attention that causes us to believe that the accompanying Statement read with notes therein, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.



6. The unaudited consolidated financial results include the interim financial results of two foreign subsidiaries which are not required to be audited/reviewed under the law of respective countries of their incorporation, whose interim financial results reflect total assets of Rs. 108.16 lakhs as at September 30, 2026 and total revenue from operation of Rs. Nil and Rs. Nil, net profit after tax of Rs. 4.53 lakhs and Rs. (0.22) lakhs and total comprehensive income of Rs. 1.06 Lakhs and Rs. 1.61 lakhs for the quarter and half year ended September 30, 2026 respectively, and net cash outflow of Rs. 0.10 lakhs for the half year ended September 30, 2026 as considered in the statement. According to the information and explanations given to us by the management, these interim financial results are not material to the Group.

   Our conclusion on the Statement is not modified in respect of the above matter.

For Singhi and Co.
Chartered Accountants
Firm Reg. No. 302049E

Bimal Kumar Sipani
Partner
Membership No. 088926
UDIN: 26088926PZHCNJ1486

Place: Noida (Delhi-NCR)
Date: November 13, 2026

SUNLOC

SUNIL HEALTHCARE LIMITED

Registered Office
38E/252-A, Vijay Tower, Shahpurjat
New Delhi-110049
Email: info@sunilhealthcare.com; website: www.sunilhealthcare.com
CIN : L24302DL1973PLC189662

STATEMENT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30TH SEPTEMBER 2026

Rs. in Lakhs

Particulars		Standalone					Year Ended	Consolidated					Year Ended
		Quarter ended			Half Year Ended		Standalone	Quarter ended			Half Year Ended		Consolidated
		30th September 2026	30th June 2026	30th September 2025	30th September 2026	30th September 2025	31st March 2026	30th September 2026	30th June 2026	30th September 2025	30th September 2026	30th September 2025	31st March 2026
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Revenue from Operations	1,922.48	1,898.59	2,351.76	3,821.07	4,615.96	8,771.92	1,922.48	1,898.59	2,351.76	3,821.07	4,615.96	8,771.92
2	Other Income	118.27	22.76	21.02	141.03	44.44	114.31	118.84	22.76	42.06	141.60	127.87	218.23
3	**Total Income (1+2)**	2,040.75	1,921.35	2,372.78	3,962.10	4,660.40	8,886.23	2,041.32	1,921.35	2,393.82	3,962.67	4,743.83	8,990.15
4	**Expenses**												
	a) Cost of Materials consumed	945.25	942.62	863.60	1,887.87	1,806.38	3,252.39	945.25	942.62	863.60	1,887.87	1,806.38	3,252.39
	b) Purchase of Stock-in-trade	-	4.16	0.11	4.16	2.66	15.45	-	4.16	0.11	4.16	2.66	15.45
	c) Changes in inventories of finished goods, work-in-progress and stock-in-trade	(153.33)	(235.25)	(53.19)	(388.58)	(51.59)	(107.86)	(153.33)	(235.25)	(53.19)	(388.58)	(51.59)	10.91
	d) Employees benefit expenses	305.82	317.01	332.15	622.83	652.34	1,288.86	305.82	317.01	332.15	622.83	652.34	1,288.86
	e) Finance Costs	172.51	149.67	139.58	322.18	283.94	616.31	172.51	149.67	139.58	322.18	283.94	616.31
	f) Depreciation and amortisation expense	146.29	145.73	164.26	292.02	330.42	643.56	146.29	145.73	164.26	292.02	330.42	643.56
	g) Other Expenses	598.82	572.58	816.69	1,171.40	1,485.66	2,927.08	594.86	577.33	816.94	1,172.19	1,486.14	2,928.08
	Total Expenses	2,015.36	1,896.52	2,263.20	3,911.88	4,509.81	8,635.79	2,011.40	1,901.27	2,263.45	3,912.67	4,510.29	8,755.56
5	**Profit before Exceptional Items and tax (3-4)**	25.39	24.83	109.58	50.22	150.59	250.44	29.92	20.08	130.37	50.00	233.54	234.59
6	**Exceptional Items Income / (Expenses)**	-	-	-	-	-	(958.25)	-	-	-	-	-	(11.59)
7	**Profit before tax after exceptional items**	25.39	24.83	109.58	50.22	150.59	(707.81)	29.92	20.08	130.37	50.00	233.54	223.00
8	**Tax Expenses (Net)**	6.13	(26.23)	30.68	(20.10)	43.07	(177.60)	6.13	(26.23)	30.68	(20.10)	43.07	(177.60)
	a) Current Tax	-	-							-			
	i) For Current year	6.96	29.77	26.73	36.73	38.86	38.74	6.96	29.77	26.73	36.73	38.86	38.74
	ii) For Earlier year	-	-	-	-	-	0.14	-	-	-	-	-	0.14
	b) Deferred Tax Charged/(Credit)												
	i) For Current year	(0.83)	(56.00)	3.95	(56.83)	4.21	(216.48)	(0.83)	(56.00)	3.95	(56.83)	4.21	(216.48)
	ii) For Earlier year	-	-	-	-		-	-		-	-		-
9	**Profit/(loss) after tax**	19.26	51.06	78.90	70.32	107.52	(530.21)	23.79	46.31	99.69	70.10	190.47	400.60
10	**Other Comprehensive Income (OCI)**	(14.21)	268.70	(12.72)	254.49	(25.44)	(51.73)	(17.68)	274.00	(46.35)	256.32	(100.74)	(146.95)
	a) Items that will not be reclassified to Profit or Loss (net of tax)	(14.21)	268.70	(12.72)	254.49	(25.44)	(51.73)	(14.21)	268.70	(12.72)	254.49	(25.44)	(51.73)
	b) Items that will be reclassified to Profit or Loss (net of tax)	-	-	-	-	-	-	(3.47)	5.30	(33.63)	1.83	(75.30)	(95.22)
11	**Total Comprehensive Income**	5.05	319.76	66.18	324.81	82.08	(581.94)	6.11	320.31	53.34	326.42	89.73	253.65
12	Paid-up equity share capital (Face value per share Rs.10/-)	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48	1,025.48
13	Other Equity (excluding revaluation reserve)				-		4,136.33				-		4,313.00
14	Earning per share of Rs.10/- each(not annualised)												
	(a) Basic (Rs.)	0.19	0.50	0.77	0.69	1.05	(5.17)	0.23	0.45	0.97	0.68	1.86	3.91
	(b) Diluted (Rs.)	0.19	0.50	0.77	0.69	1.05	(5.17)	0.23	0.45	0.97	0.68	1.86	3.91

SUNIL HEALTHCARE LTD.
38E/252A
3rd Floor
Vijay Tower
Sahapur Jat
New Delhi
110049

Rs. in Lakhs

2 Statement of Assets and Liabilities

Particulars	Standalone		Consolidated	
	As at 30th September 2026	As at 31st March 2026	As at 30th September 2026	As at 31st March 2026
	Un-audited	Audited	Un-audited	Audited
A **ASSETS**				
1 **Non Current Assets**				
(a) **Fixed Assets**				
(i) Property, Plant and Equipment	5,182.36	5,438.48	5,182.36	5,438.48
(ii) Capital Work-in-Progress	410.57	177.19	410.57	177.19
(iii) Right of Use Assets	3,111.65	3,144.81	3,111.65	3,144.81
(iv) Other Intangible Assets	0.83	1.97	0.83	1.97
(b) **Financial Assets**				
(i) Investment	-	-	-	-
(ii) Other financial assets	91.03	186.90	92.69	188.55
(c) Other non-current Assets	172.20	113.69	172.20	113.69
2 **Current Assets**				
(a) Inventories	1,964.82	1,874.26	1,964.82	1,874.26
(b) Financial Assets				
(i) Trade Receivables	5,017.77	4,368.53	5,164.14	4,512.85
(ii) Cash and Cash Equivalents	7.53	6.53	8.30	7.39
(iii) Bank Balance other than (ii) above	429.26	225.48	429.26	225.48
(iv) Loans	-	-	-	-
(v) Other Financial Assets	340.54	378.81	340.78	379.05
(c) Other Current Assets	437.59	315.35	509.81	386.83
TOTAL ASSETS	**17,166.15**	**16,232.00**	**17,387.41**	**16,450.55**
B **EQUITY AND LIABILITIES**				
1 **Equity**				
(a) Equity Share Capital	1,025.48	1,025.48	1,025.48	1,025.48
(b) Other Equity	6,082.94	5,758.13	6,261.25	5,934.80
2 **Non Current Liabilities**				
(a) Financial Liabilities				
(i) Borrowings	1,937.84	1,550.59	1,937.84	1,550.59
(ii) Other Financial Liabilities	249.01	238.09	249.01	238.09
(b) Provisions	129.92	148.72	129.92	148.72
(c) Deferred Tax Liabilities (Net)	558.18	902.66	558.18	902.66
(d) Other Non-Current Liabilities	4.68	16.10	4.68	16.10
3 **Current Liabilties**				
(a) Financial Liabilities				
(i) Borrowings	4,677.90	4,027.89	4,677.90	4,027.89
(ii) Trade Payables				
Total Outstanding dues of Micro enterprises and small enterprises ; and	262.27	244.61	262.27	244.61
Total Outstanding dues of Creditors other than Micro enterprises and small enterprises	1,157.06	1,320.15	1,191.40	1,353.52
(iii) Other Financial Liabilities	614.51	585.71	614.51	585.71
(b) Other Current Liabilities	269.85	249.74	278.46	258.25
(c) Provisions	141.35	141.35	141.35	141.35
(d) Current tax liabilities(Net)	55.16	22.78	55.16	22.78
TOTAL - EQUITY AND LIABILITIES	**17,166.15**	**16,232.00**	**17,387.41**	**16,450.55**
	-	-	-	

SUNIL HEALTHCARE LTD.
38E/252A
3rd Floor
Vijay Tower
Sahapur Jat
New Delhi
110049

Rs. in Lakhs

Cash Flow Statement

3	Particulars	Standalone		Consolidated	
		For the Half year ended 30th Sep 2026	For the Half year ended 30th Sep 2025	For the Half year ended 30th Sep 2026	For the Half year ended 30th Sep 2025
		Un-audited	Un-audited	Un-audited	Un-audited
	A. Cash Flow From Operating Activities				
	Profit/(loss) before Tax	50.22	150.59	50.00	233.54
	Adjustment for :				
	Finance Costs	322.18	283.94	322.18	283.94
	Depreciation and Amortization Expenses	292.02	330.42	292.02	330.42
	Net (Profit)/Loss on sales/discard of Property ,Plant and Equipment	0.12	(0.01)	0.12	(0.01)
	Provision for Expected Credit Loss	-	71.80	-	71.80
	Interest Income	(14.16)	(16.51)	(14.16)	(13.30)
	Claim against Property, Plant and Equipment	(72.46)	-	(72.46)	-
	Unwinding of Interest Free Security Deposit	(11.42)	-	(11.42)	-
	Unspent liabilities written back	(27.58)	(0.26)	(27.58)	(0.26)
	Unrealised (gain)/loss foreign currency transactions and translation	(17.62)	(56.00)	(16.36)	(131.31)
	Operating profit before working capital changes	**521.30**	**763.97**	**522.34**	**774.82**
	Changes in working Capital:				
	(Increase)/Decrease in Inventories	(90.56)	(40.25)	(90.56)	(76.52)
	(Increase)/Decrease in Trade and other Receivables	(763.24)	162.38	(765.46)	167.51
	Increase /(Decrease) in Trade and other payable	(84.13)	502.11	(83.04)	523.53
	Cash generation from Operation	**(416.63)**	**1,388.21**	**(416.72)**	**1,389.34**
	Refund/(Payment) of Direct Taxes	(4.35)	(2.22)	(4.35)	(3.25)
	Net Cash generated from/ (used in) Operating Activities	**(420.98)**	**1,385.99**	**(421.07)**	**1,386.09**
	B. Cash Flow from Investing Activities				
	Purchase of Property, Plant and Equipment & Intangible Assets including Capital work-in-progres	(336.67)	(235.46)	(336.67)	(235.46)
	Proceeds from sale of/claim against Property, Plant and Equipment	114.65	0.05	114.65	0.05
	Investment in Mutual Funds	-	(10.00)	-	(10.00)
	Movement in Term Deposits	(114.03)	32.20	(114.03)	32.20
	Interest Received	10.25	16.36	10.25	16.36
	Net Cash generated from/ (used in) Investing Activities	**(325.80)**	**(196.85)**	**(325.80)**	**(196.85)**
	C. Cash Flow from Financing Activities				
	Receipts from Non Current Borrowings	515.00	27.75	515.00	27.75
	Repayment of Non Current Borrowings	(198.56)	(322.51)	(198.56)	(322.51)
	Loan (repaid)/receipt to/ from a Director	283.02	3.00	283.02	3.00
	Receipts/(Repayment) of Current Borrowings (Net)	418.91	(607.13)	418.91	(607.13)
	Finance Costs Paid	(270.59)	(282.20)	(270.59)	(282.20)
	Net Cash generated from/ (used in) Financing Activities	**747.78**	**(1,181.09)**	**747.78**	**(1,181.09)**
	Net Increase/ (Decrease) in Cash and Cash Equivalents (A+B+C)	1.00	8.05	0.91	8.15
	Add : Opening Cash and Cash Equivalents	6.53	2.37	7.39	3.07
	Closing Cash and Cash Equivalents	**7.53**	**10.42**	**8.30**	**11.22**

4 As the Company's business fall within a single primary business segment viz. sale of capsule, the disclosure requirement of Indian Accounting Standard (Ind AS-108) "Operating Segments" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder, is not applicable.

5 The Company has decided to exercise the option permitted under section 200 of the Income Tax Act, 2025 as introduced by the Taxation Laws (Amendment) Ordinance, 2019. Accordingly, the Company has recognised provision for Income Tax for the previous quarter and remeasured its deferred tax assets and liabilities, basis the rate prescribed in the said section. Further, the Company has remeasured the deferred tax liability on gain on fair valuation of leasehold land at a rate without indexation as per section 197 of the Income Tax Act, 2025 resulting net reversal of deferred tax liabilities.The full impact of these changes have been recognised during the previous quarter.

6 The above results were reviewed by the Audit Committee and approved by the Board of Directors in their respective meetings held on November 13, 2026 .

SUNIL HEALTHCARE LTD.
38E/252A
3rd Floor
Vijay Tower
Sahapur Jat
New Delhi
110049

Anil Khaitan
(Chairman cum Managing Director)
DIN 00759951

Place: NEW DELHI
Date: 13-11-2026